News

The increase in revenue was primarily due to an increase in revenue from the company’s contract with the National Institute of Allergy and Infectious Diseases (NIAID) of $2.7m

The decision to restart the oral solid dose products to US was based on the US Food and Drug Administration’s (FDA) decision to lift its import alert at

The tie up is expected to advance the use of stem cells for cell therapies and research. Sistemic CEO Jim Reid said they have been using SistemQC microRNA

Vemurafenib, a ‘BRAF-inhibitor,’ is designed to selectively target and inhibit a mutated form of the BRAF protein, a component of the RAS-RAF pathway involved in normal cell growth

NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials Th company intends to recruit around 100-200 patients who have already participated

Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B

With this new facility, EMD Millipore expects to offer training and validation services to its customers operating in China. The facility will allow local and regional customers to

The approval was given on the basis of results from prospective, open-label, single-arm Phase II study, in which 75% of patients (21 of 28) experienced a reduction of

The company has posted a net loss of $2.69m for the third quarter 2011, or $0.13 loss per diluted share, compared to net loss of $2.71m, or $0.15